Table 3.

Comparison between optimal LSS and reference design for estimating AUC^a_0-τ after oral MMF administration

Pharmacokinetic Sampling Schedule	Sampling times (hr)	Root mean sMSEb % (AUC0-τ)	Mean relative bias (rbias)% (AUC0-τ)	Pearson r	Percent individuals with rbias% > 10%
Q12 hr oral MMF administration
Reference design	Pre-dose, 1, 2, 4, 6, 8, 10	14.82	7.31	0.970	0.3%
6 hr duration LSS	Pre-dose, 0.25, 1, 2, 5	16.23	8.57	0.961	0.7%
4 hr duration LSS	Pre-dose, 0.25, 1.25, 2, 4	16.29	8.55	0.961	0.5%
2 hr duration LSS	Pre-dose, 0.25, 1.25, 1.75,2	16.82	9.5	0.944	1.5%
Q8 hr oral MMF administration
Reference design	Pre-dose, 1, 2, 4, 6, 8	16.06	8.31	0.964	0.4%
6 hr duration LSS	Pre-dose, 0.25, 1, 2, 5	16.69	8.71	0.963	0.7%
4 hr duration LSS	Pre-dose, 0.25, 1, 2, 3	16.86	8.69	0.962	0.7%
2 hr duration LSS	Pre-dose, 0.25, 1.25, 1.75,2	16.90	8.92	0.957	1.5%

^aAUC_0-τ where τ is dosing frequency, so AUC_0–12hr for PO MMF administered Q12 hrs and AUC_0–8hr for PO MMF administered Q8hrs;

^bsMSE: scaled mean square error.